175 related articles for article (PubMed ID: 35878026)
1. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.
Mao Z; Nesterenko PA; McLaughlin J; Deng W; Burton Sojo G; Cheng D; Noguchi M; Chour W; DeLucia DC; Finton KA; Qin Y; Obusan MB; Tran W; Wang L; Bangayan NJ; Ta L; Chen CC; Seet CS; Crooks GM; Phillips JW; Heath JR; Strong RK; Lee JK; Wohlschlegel JA; Witte ON
Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2203410119. PubMed ID: 35878026
[TBL] [Abstract][Full Text] [Related]
2. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
3. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing.
Pan Y; Phillips JW; Zhang BD; Noguchi M; Kutschera E; McLaughlin J; Nesterenko PA; Mao Z; Bangayan NJ; Wang R; Tran W; Yang HT; Wang Y; Xu Y; Obusan MB; Cheng D; Lee AH; Kadash-Edmondson KE; Champhekar A; Puig-Saus C; Ribas A; Prins RM; Seet CS; Crooks GM; Witte ON; Xing Y
Proc Natl Acad Sci U S A; 2023 May; 120(21):e2221116120. PubMed ID: 37192158
[TBL] [Abstract][Full Text] [Related]
4. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
5. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
6. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
Johnson LE; McNeel DG
Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
[TBL] [Abstract][Full Text] [Related]
7.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
8. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
9. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
10. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
11. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
12. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
13. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
[TBL] [Abstract][Full Text] [Related]
14. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
15. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells.
Lyons GE; Roszkowski JJ; Man S; Yee C; Kast WM; Nishimura MI
Cancer Immunol Immunother; 2006 Sep; 55(9):1142-50. PubMed ID: 16374636
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
18. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S; Glaser M; Pecoraro M; Bräunlein E; Mall S; Klar R; Effenberger M; Albers J; Bianchi HO; Peper J; Yusufi N; Busch DH; Stevanović S; Mann M; Antes I; Krackhardt AM
Front Immunol; 2019; 10():1485. PubMed ID: 31316521
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
[TBL] [Abstract][Full Text] [Related]
20. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
